These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34623894)

  • 1. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma.
    Hall WA; Dawson LA; Hong TS; Palta M; Herman JM; Evans DB; Tsai S; Ferrone CR; B Fleming J; Chang DT; Crane C; Koong AC; Oar A; Parikh P; Erickson B; Hoffe S; Goodman KA
    J Clin Oncol; 2021 Dec; 39(34):3773-3777. PubMed ID: 34623894
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities.
    Robin TP; Goodman KA
    Chin Clin Oncol; 2017 Jun; 6(3):28. PubMed ID: 28705005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
    Jiang W; Haque W; Verma V; Butler EB; Teh BS
    Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
    Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
    Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma.
    Chapman BC; Gleisner A; Rigg D; Meguid C; Goodman K; Brauer B; Gajdos C; Schulick RD; Edil BH; McCarter MD
    J Surg Oncol; 2018 Apr; 117(5):1073-1083. PubMed ID: 29448308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
    Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
    Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
    Wu G; Baine MJ; Zhao N; Li S; Li X; Lin C
    BMC Cancer; 2019 Oct; 19(1):977. PubMed ID: 31640607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity.
    Pollom EL; Alagappan M; von Eyben R; Kunz PL; Fisher GA; Ford JA; Poultsides GA; Visser BC; Norton JA; Kamaya A; Cox VL; Columbo LA; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):918-25. PubMed ID: 25585785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy for locally advanced pancreatic ductal adenocarcinoma.
    Buss EJ; Kachnic LA; Horowitz DP
    Semin Oncol; 2021 Feb; 48(1):106-110. PubMed ID: 33771355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
    Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C
    BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma.
    Koong AJ; Toesca DAS; Baclay JRM; Pollom EL; von Eyben R; Koong AC; Chang DT
    Pract Radiat Oncol; 2020; 10(4):274-281. PubMed ID: 32119922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Body Radiation Therapy for Pancreatic Cancer.
    Goodman KA
    Cancer J; 2016; 22(4):290-5. PubMed ID: 27441749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
    Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
    Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Setup Management for Stereotactic Body Radiation Therapy of Patients With Pancreatic Cancer Treated via the Breath-Hold Technique.
    Teboh RF; Srinivasan S; Ng SP; Aliru ML; Herman JM
    Pract Radiat Oncol; 2020; 10(4):e280-e289. PubMed ID: 31669403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer: A single center experience.
    Jumeau R; Delouya G; Roberge D; Donath D; Béliveau-Nadeau D; Campeau MP
    Dig Liver Dis; 2018 Apr; 50(4):396-400. PubMed ID: 29326012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study.
    Comito T; Cozzi L; Clerici E; Franzese C; Tozzi A; Iftode C; Navarria P; D'Agostino G; Rimassa L; Carnaghi C; Personeni N; Tronconi MC; De Rose F; Franceschini D; Ascolese AM; Fogliata A; Tomatis S; Santoro A; Zerbi A; Scorsetti M
    Technol Cancer Res Treat; 2017 Jun; 16(3):295-301. PubMed ID: 27311310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question.
    Scorsetti M; Comito T; Franceschini D; Franzese C; Prete MG; D'Alessio A; Bozzarelli S; Rimassa L; Santoro A
    Br J Radiol; 2020 Feb; 93(1106):20190627. PubMed ID: 31825664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).
    Pavic M; Niyazi M; Wilke L; Corradini S; Vornhülz M; Mansmann U; Al Tawil A; Fritsch R; Hörner-Rieber J; Debus J; Guckenberger M; Belka C; Mayerle J; Beyer G
    Radiat Oncol; 2022 Jan; 17(1):18. PubMed ID: 35078490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings.
    Franke AJ; Rosati LM; Pawlik TM; Kumar R; Herman JM
    Semin Oncol; 2015 Feb; 42(1):144-62. PubMed ID: 25726059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era.
    Hue JJ; Dorth J; Sugumar K; Hardacre JM; Ammori JB; Rothermel LD; Saltzman J; Mohamed A; Selfridge JE; Bajor D; Winter JM; Ocuin LM
    Am Surg; 2021 Sep; 87(9):1386-1395. PubMed ID: 34382877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.